{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:31:08Z","timestamp":1788546668556,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12674-3","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:54:30Z","timestamp":1770137670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world untreated risk of hospitalization and death in a nirmatrelvir\/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Kristen","family":"Migliaccio-Walle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tendai","family":"Mugwagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Cha-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Quercia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bergroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendwas","family":"Dzingina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"12674_CR1","unstructured":"Paxlovid. European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid. Accessed January 10, 2025."},{"key":"12674_CR2","unstructured":"US Food and Drug Administration. FDA approves first oral antiviral for treatment of COVID-19 in adults. U.S. Food and Drug administration. 2024 August 9. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults. Accessed January 10, 2025."},{"key":"12674_CR3","unstructured":"U.S. Food and Drug Administration. EUA 105 Pfizer Paxlovid LOA 01292024. https:\/\/www.paxlovidinformation.com\/pdfs\/EUA-105-Pfizer-Paxlovid-LOA-01292024.pdf. Published online January 29, 2024."},{"key":"12674_CR4","unstructured":"PAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets) for patients. Accessed April 8, 2025. https:\/\/www.paxlovidinformation.com\/"},{"key":"12674_CR5","doi-asserted-by":"publisher","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, Nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15). https:\/\/doi.org\/10.1056\/nejmoa2118542.","DOI":"10.1056\/nejmoa2118542"},{"key":"12674_CR6","unstructured":"CDC. COVID-19 treatment clinical care for outpatients. COVID-19. 2024 December 20. https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/outpatient-treatment.html. Accessed January 11, 2025."},{"key":"12674_CR7","doi-asserted-by":"crossref","unstructured":"Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022. 2024, September;78(7):e250\u2013349.","DOI":"10.1093\/cid\/ciac724"},{"key":"12674_CR8","unstructured":"IDSA guidelines on the treatment and management of patients with COVID-19. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/. Accessed January 19, 2025."},{"key":"12674_CR9","doi-asserted-by":"publisher","unstructured":"Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 - United States, April-September 2022. Am J Transpl. 2023;23(1). https:\/\/doi.org\/10.1016\/j.ajt.2022.12.004.","DOI":"10.1016\/j.ajt.2022.12.004"},{"key":"12674_CR10","doi-asserted-by":"publisher","unstructured":"Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for Early COVID-19 in a large U.S. Health System: a population-based cohort study. Ann Intern Med. 2023;176(1). https:\/\/doi.org\/10.7326\/m22-2141.","DOI":"10.7326\/m22-2141"},{"issue":"4","key":"12674_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.7326\/M22-1286","volume":"176","author":"KE Kip","year":"2023","unstructured":"Kip KE, McCreary EK, Collins K, et al. Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study. Ann Intern Med. 2023;176(4):496\u2013504.","journal-title":"Ann Intern Med"},{"key":"12674_CR12","doi-asserted-by":"publisher","unstructured":"Zhou X, Kelly SP, Liang C, et al. Real-world effectiveness of nirmatrelvir\/ritonavir in preventing hospitalization among patients with COVID-19 at high risk for severe disease in the United States: a nationwide population-based cohort study. bioRxiv. https:\/\/doi.org\/10.1101\/2022.09.13.22279908. Published online September 14, 2022.","DOI":"10.1101\/2022.09.13.22279908"},{"key":"12674_CR13","unstructured":"World Health Organization. Therapeutics and COVID-19: living guideline, 10 November 2023. November 10, 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2023.2. Accessed January 30, 2025."},{"key":"12674_CR14","unstructured":"A timeline of COVID-19 variants. Verywell Health. 2022 September 28. https:\/\/www.verywellhealth.com\/covid-variants-timeline-6741198. Accessed January 16, 2025."},{"key":"12674_CR15","unstructured":"CDC. CDC Museum COVID-19 Timeline. Centers for Disease Control and Prevention. 2023 March 15. https:\/\/www.cdc.gov\/museum\/timeline\/covid19.html. Accessed January 16, 2025."},{"key":"12674_CR16","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, et al. Chapter, 7: systematic reviews of etiology and risk. JBI Man Evidence Synth. Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. JBI; 2020.","DOI":"10.46658\/JBIRM-17-06"},{"issue":"5","key":"12674_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1046\/J.1524-4733.2002.55150.x","volume":"5","author":"E Schechtman","year":"2002","unstructured":"Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat-which of these should we use? Value Health. 2002;5(5):431\u201336.","journal-title":"Value Health"},{"key":"12674_CR18","doi-asserted-by":"publisher","unstructured":"Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023;23(7). https:\/\/doi.org\/10.1016\/s1473-3099(23)00118-4.","DOI":"10.1016\/s1473-3099(23)00118-4"},{"key":"12674_CR19","doi-asserted-by":"publisher","unstructured":"Cowman K, Miller A, Guo Y, et al. Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir\/ritonavir versus molnupiravir in high-risk COVID-19 outpatients. J Antimicrob Chemother. 2023;78(7). https:\/\/doi.org\/10.1093\/jac\/dkad154.","DOI":"10.1093\/jac\/dkad154"},{"key":"12674_CR20","doi-asserted-by":"publisher","unstructured":"Al-Obaidi MM, Gungor AB, Murugapandian S, et al. The impact of nirmatrelvir-ritonavir in reducing hospitalizations among high-risk patients with SARS-CoV-2 during the Omicron predominant era. Am J Med. 2023;136(6). https:\/\/doi.org\/10.1016\/j.amjmed.2023.02.022.","DOI":"10.1016\/j.amjmed.2023.02.022"},{"key":"12674_CR21","doi-asserted-by":"publisher","unstructured":"Lin DY, Abi Fadel F, Huang S, et al. Nirmatrelvir or molnupiravir use and severe outcomes from Omicron infections. JAMA Netw Open. 2023;6(9). https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35077.","DOI":"10.1001\/jamanetworkopen.2023.35077"},{"key":"12674_CR22","unstructured":"Kim CY, Pallotta A, Kim A, et al. Evaluation of COVID-19 monoclonal antibodies and oral antiviral therapies in non-hospitalized patients at Cleveland Clinic Health System. In: J Am Coll Clin Pharm. Vol. 6. Wiley; 2023. p. 1387\u2013517."},{"key":"12674_CR23","doi-asserted-by":"publisher","unstructured":"Li M, Zhang QS, Liu XL, Wang HL, Liu W. Adverse events associated with Nirmatrelvir\/Ritonavir: a pharmacovigilance analysis based on FAERS. Pharmaceuticals. 2022;15(12). https:\/\/doi.org\/10.3390\/ph15121455.","DOI":"10.3390\/ph15121455"},{"key":"12674_CR24","doi-asserted-by":"publisher","unstructured":"Razonable RR, O\u2019Horo JC, Hanson SN, et al. Comparable outcomes for bebtelovimab and ritonavir-boosted nirmatrelvir treatment in high-risk patients with Coronavirus Disease-2019 during severe acute respiratory syndrome Coronavirus 2 BA.2 Omicron epoch. J Infect Dis. 2022;226(10). https:\/\/doi.org\/10.1093\/infdis\/jiac346.","DOI":"10.1093\/infdis\/jiac346"},{"key":"12674_CR25","doi-asserted-by":"publisher","unstructured":"Ranganath N, O\u2019Horo JC, Challener DW, et al. Rebound phenomenon after Nirmatrelvir\/Ritonavir treatment of Coronavirus Disease 2019 (COVID-19) in high-risk Persons. Clin Infect Dis. 2023;76(3). https:\/\/doi.org\/10.1093\/cid\/ciac481.","DOI":"10.1093\/cid\/ciac481"},{"key":"12674_CR26","doi-asserted-by":"publisher","unstructured":"Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after Paxlovid treatment -California , December 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(25). https:\/\/doi.org\/10.15585\/mmwr.mm7125e2.","DOI":"10.15585\/mmwr.mm7125e2"},{"key":"12674_CR27","doi-asserted-by":"publisher","unstructured":"Kukreja I, Gaur A, Upadhyay N, et al. RWD129 a comparison of ICU admission rate and related Cost among patients taking nirmatrelvir and ritonavir combination versus molnupiravir for treatment of mild to moderate COVID-19 in the US. Value Health. 2022;25(12). https:\/\/doi.org\/10.1016\/j.jval.2022.09.2354.","DOI":"10.1016\/j.jval.2022.09.2354"},{"key":"12674_CR28","doi-asserted-by":"publisher","unstructured":"Vora SB, Englund JA, Trehan I, et al. Monoclonal antibody and antiviral therapy for mild-to-moderate COVID-19 in pediatric patients. Pediatr Infect Dis J. 2023;42(1). https:\/\/doi.org\/10.1097\/inf.0000000000003740.","DOI":"10.1097\/inf.0000000000003740"},{"key":"12674_CR29","doi-asserted-by":"publisher","unstructured":"Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in Nonhospitalized Vaccinated patients with Coronavirus Disease 2019. Clin Infect Dis. 2023;76(4). https:\/\/doi.org\/10.1093\/cid\/ciac673.","DOI":"10.1093\/cid\/ciac673"},{"key":"12674_CR30","doi-asserted-by":"publisher","unstructured":"Faust JS, Kumar A, Shah J, et al. Oral nirmatrelvir and ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized adults aged 18\u201350 years. Clin Infect Dis. 2023;77(9). https:\/\/doi.org\/10.1093\/cid\/ciad400.","DOI":"10.1093\/cid\/ciad400"},{"key":"12674_CR31","doi-asserted-by":"publisher","unstructured":"Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023;95(6). https:\/\/doi.org\/10.1002\/jmv.28869.","DOI":"10.1002\/jmv.28869"},{"key":"12674_CR32","doi-asserted-by":"publisher","unstructured":"Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;23(6). https:\/\/doi.org\/10.1016\/s1473-3099(23)00011-7.","DOI":"10.1016\/s1473-3099(23)00011-7"},{"key":"12674_CR33","doi-asserted-by":"publisher","unstructured":"Kane AM, Keenan EM, Lee K, et al. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: a retrospective observational study. JACCP JAm Coll Clin Pharm. 2023;6(1). https:\/\/doi.org\/10.1002\/jac5.1729.","DOI":"10.1002\/jac5.1729"},{"key":"12674_CR34","unstructured":"Henderson H, Wohl DA, Fischer W, et al. COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT. Top Antivir Med. 2023;31(2). https:\/\/www.embase.com\/search\/results?subaction=viewrecord%26id=L641189831%26from=export."},{"key":"12674_CR35","doi-asserted-by":"publisher","first-page":"e073312","DOI":"10.1136\/bmj-2022-073312","volume":"381","author":"Y Xie","year":"2023","unstructured":"Xie Y, Bowe B, Al-Aly Z. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;381:e073312.","journal-title":"BMJ"},{"key":"12674_CR36","doi-asserted-by":"publisher","unstructured":"Butt AA, Yan P, Shaikh OS, Talisa VB, Omer SB, Mayr FB. Nirmatrelvir\/Ritonavir use and hospitalizations or death in a Previously uninfected Nonhospitalized high-risk population with COVID-19: a Matched cohort study. J Infect Dis. 2024;229(1). https:\/\/doi.org\/10.1093\/infdis\/jiad393.","DOI":"10.1093\/infdis\/jiad393"},{"key":"12674_CR37","doi-asserted-by":"publisher","unstructured":"Gentry CA, Nguyen P, Thind SK, Kurdgelashvili G, Williams RJ. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Infect. 2023;86(3). https:\/\/doi.org\/10.1016\/j.jinf.2023.01.018.","DOI":"10.1016\/j.jinf.2023.01.018"},{"key":"12674_CR38","doi-asserted-by":"publisher","unstructured":"Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. Ann Intern Med. 2023;176(6). https:\/\/doi.org\/10.7326\/m22-3565.","DOI":"10.7326\/m22-3565"},{"issue":"3","key":"12674_CR39","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1097\/MJT.0000000000001744","volume":"31","author":"AS Cha-Silva","year":"2024","unstructured":"Cha-Silva AS, Gavaghan MB, Bergroth T, et al. Effectiveness of nirmatrelvir-ritonavir for the prevention of COVID-19-related hospitalization and mortality: a systematic literature review. Am J Ther. 2024;31(3):e246\u201357.","journal-title":"Am J Ther"},{"issue":"12","key":"12674_CR40","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15585\/mmwr.mm7112e2","volume":"71","author":"CA Taylor","year":"2022","unstructured":"Taylor CA, Whitaker M, Anglin O, et al. COVID-19-associated hospitalizations among adults during SARS-CoV-2 Delta and Omicron variant predominance, by race\/ethnicity and vaccination status - COVID-NET, 14 states, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):466\u201373.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"12674_CR41","unstructured":"Institute for Clinical and Economic Review. Special assessment of outpatient treatments for COVID-19. ICER. August 26, 2021. https:\/\/icer.org\/assessment\/covid-19-2022\/. Accessed January 19, 2025."},{"issue":"48","key":"12674_CR42","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.15585\/mmwr.mm7148e2","volume":"71","author":"MM Shah","year":"2022","unstructured":"Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 - United States, April-September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531\u201337.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"12674_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jval.2023.11.003","volume":"27","author":"J Carlson","year":"2024","unstructured":"Carlson J, Foos V, Kasle A, et al. Cost-effectiveness of oral nirmatrelvir\/ritonavir in patients at high risk for progression to severe COVID-19 in the United States. Value Health. 2024;27(2):164\u201372.","journal-title":"Value Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12674-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:16:11Z","timestamp":1772622971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12674-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12674"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12674-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KMW, CLG, DC, and DLV are employees of Curta Inc., which received funding from Pfizer in connection with the development of this manuscript . TM, ACS, RQ, TB, MMM, MD are employees and stockholders of Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"488"}}